## [Investors](/investors "Investors") We aim for sustainable performance over time to benefit patients, employees, shareholders and society. Solid financial results and maintaining the trust of society underpin our ability to create value for our company, our shareholders and society. ![Cover image for the Q4 2025 results presentation](/sites/novartis_com/files/styles/cta_image/public/2026-01/novartis-investor-q4-full-year-2025-results-media-content.jpg?h=afdc3185&itok=35EuWuwE "Cover image for the Q4 2025 results presentation") ## Third quarter results 2026 October 27, 2026 | Basel, Switzerland Press release: [English (PDF 0.3 MB)](/sites/novartis_com/files/q3-2026-media-release-en.pdf) | [Deutsch (PDF 0.3 MB)](/sites/novartis_com/files/q3-2026-media-release-de.pdf) [Interim financial report (PDF 0.4 MB)](/sites/novartis_com/files/q3-2026-interim-financial-report-en.pdf) [Watch the webcast](https://edge.media-server.com/mmc/p/8bq2jabb "(opens in a new window)") [Download the presentation (PDF 3.2 MB)](/sites/novartis_com/files/q3-2026-investor-presentation.pdf "q3-2026-investor-presentation.pdf") [Download the podcast (MP3 34 MB)](/sites/novartis_com/files/2026-10/q3-2026-investor-presentation.mp3) [Learn more](/investors/financial-data/quarterly-results "Learn more") ![Walkway at the entrance of the Novartis Campus in Basel, Switzerland](/sites/novartis_com/files/styles/cta_image/public/2021-08/investors-landing-campus-entry-walkway-image.jpg?h=e2bcc475&itok=AaL-3e8z "Novartis Campus in Basel, Switzerland") ## Investors event calendar View recent presentations and learn more about upcoming events. November 05, 2026 **ZKB Swiss Equity Conference** Zurich, Switzerland [Learn more](/investors/event-calendar "Learn more") --- ![Group of warm clothed women, seated outside, smiling and laughing](/sites/novartis_com/files/styles/cta_image/public/2023-11/group-of-warm-clothed-people-smilling-and-laughing.jpg?h=ba6ae691&itok=QKFwjDHd "Group of warm clothed women, seated outside, smiling and laughing") ## Environmental, Social and Governance (ESG) Novartis aims to hold itself to the highest standards of sustainability and ethical business practices. We take bold steps to increase access to medicines, tackle complex global health challenges, and do our part as a responsible corporate citizen. [Learn more](/esg "Learn more") ESG updates: [July 2026 (PDF 1.2 MB)](/sites/novartis_com/files/novartis-q2-2026-impact-and-sustainability-update.pdf "novartis-q2-2026-impact-and-sustainability-update.pdf") | [May 2026 (PDF 1,6 MB)](/sites/novartis_com/files/novartis-q1-2026-impact-and-sustainability-update.pdf "novartis-q1-2026-impact-and-sustainability-update.pdf") | [February 2026 (PDF 1.1 MB)](/sites/novartis_com/files/novartis-q4-2025-impact-and-sustainability-update.pdf "novartis-q4-2025-impact-and-sustainability-update.pdf") | [November 2025 (PDF 0.8 MB)](/sites/novartis_com/files/novartis-q3-2025-impact-and-sustainability-update.pdf) | [July 2025 (PDF 0.8 MB)](/sites/novartis_com/files/novartis-q2-2025-impact-and-sustainability-update.pdf) Latest updates: [Social Impact & Sustainability(PDF 2.1 MB)](/sites/novartis_com/files/2025-12-novartis-social-impact-sustainability.pdf) | [Impact & Sustainability (PDF 1.9 MB)](/sites/novartis_com/files/2024-12-novartis-impact-sustainability.pdf) | [Impact & Health Equity (PDF 9.9 MB)](/sites/novartis_com/files/2023-11-novartis-investor-impact-health-equity.pdf) We have created a set of environmental, social and governance indices to signpost where our key disclosures can be found across our publications and channels. Novartis aims to report comprehensively and transparently for all stakeholders concerned with ESG topics. [Explore the ESG indices](/esg/index "Explore the ESG indices") Stocks --- ![Business people walking on the Novartis Basel campus](/sites/novartis_com/files/styles/cta_image/public/2026-01/business-people-walking-on-novartis-basel-campus.jpg?h=4997dc06&itok=J5pcr9J8 "Business people walking on the Novartis Basel campus") ## Reporting and transparency hub Read our regulatory filings; policies, codes and guidelines that govern our activities; and environmental, social and governance (ESG) disclosures. [Learn more](/investors/reporting-and-transparency-hub "Learn more") ## Press releases [Oct 27, 2026 - Ad hoc release ### Novartis delivered sales growth and core margin expansion in Q3; raised FY core operating income guidance ](/news/media-releases/novartis-delivered-sales-growth-and-core-margin-expansion-q3-raised-fy-core-operating-income-guidance) [Oct 23, 2026 - Press release ### Novartis remibrutinib delivered comprehensive disease control in Phase III RMS trials, with proven, robust safety profile ](/news/media-releases/novartis-remibrutinib-delivered-comprehensive-disease-control-phase-iii-rms-trials-proven-robust-safety-profile) [Oct 23, 2026 - Press release ### Kisqali® shows clinically meaningful overall survival in broadest HR+/HER2- early breast cancer population at high risk of recurrence ](/news/media-releases/kisqali-shows-clinically-meaningful-overall-survival-broadest-hrher2-early-breast-cancer-population-high-risk-recurrence) [All press releases](/news/news-archive?type=media_release "All press releases") [ ### Investor relations contacts For questions about investor relations or the share registry, please contact our team. ](/contacts/investor-contacts) [ ### Stay up-to-date Stay connected to the latest news and information from Novartis. ](https://www.novartis.com/news/stay-up-to-date)